Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 78 of 183 for:    RET

XL999 Administered Intravenously to a Subject With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01945164
Expanded Access Status : No longer available
First Posted : September 18, 2013
Last Update Posted : October 21, 2014
Sponsor:
Information provided by (Responsible Party):
John Sarantopoulos, The University of Texas Health Science Center at San Antonio

Brief Summary:

Cancer is a worldwide clinical and economic problem. Conventional approaches to treating cancer include surgery, radiotherapy, and cytotoxic chemotherapy as single modalities or as combined therapies. Recently, targeted therapies including antibodies and small molecule inhibitors have also demonstrated clinical benefit. It is now possible to study different genetic lesions involved in cancer types due to advances in genomic methodologies. The investigational drug in this study, XL999 inhibits multiple receptor tyrosine kinases, including VEGF receptor (VEGFR2/KDR), platelet derived growth factor receptors (PDGFRβ), fms-like tyrosine kinase receptor 3 (FLT3), fibroblast growth factor receptors (FGFR1, FGFR3), RET, and KIT, and thus, interferes with multiple cellular processes simultaneously and will likely have effects on the integrity of tumor neovasculature and angiogenesis. Together with the ability to induce a novel cell cycle arrest, the spectrum of activities that XL999 exhibits may reduce both tumor cell proliferation and angiogenesis in the clinic.

The rationale and purpose of this maintenance study is to allow a subject receiving clinical benefit from XL999 to continue treatment.


Condition or disease Intervention/treatment
Advanced Malignancy Drug: XL999

Layout table for study information
Study Type : Expanded Access
Official Title: Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900
Study Start Date : April 2010
Actual Primary Completion Date : June 2012
Actual Study Completion Date : June 2012

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: XL999
    The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The subject is eligible to continue to receive XL999 in the absence of progressive disease and unacceptable XL999-related toxicity.

Exclusion Criteria:

  • Progressive disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01945164


Locations
Layout table for location information
United States, Texas
Cancer Therapy and Research Center at UTHSCSA
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
John Sarantopoulos
Investigators
Layout table for investigator information
Principal Investigator: John Sarantopoulos, MD University of Texas Health Science Center San Antonio

Layout table for additonal information
Responsible Party: John Sarantopoulos, Principal Investigator, The University of Texas Health Science Center at San Antonio
ClinicalTrials.gov Identifier: NCT01945164     History of Changes
Other Study ID Numbers: CTRC 10-08
HSC20100312H ( Other Identifier: UTHSCSA IRB )
First Posted: September 18, 2013    Key Record Dates
Last Update Posted: October 21, 2014
Last Verified: October 2014
Keywords provided by John Sarantopoulos, The University of Texas Health Science Center at San Antonio:
XL999
Advanced Malignancy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms